期刊
JOURNAL OF BIOMOLECULAR SCREENING
卷 16, 期 8, 页码 852-861出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1087057111412183
关键词
flavivirus; NS5 N-terminal capping enzyme (CE); high-throughput screening; drug development; anti-infective drugs; fluorescence polarization (FP)
资金
- Rocky Mountain Regional Center for Excellence (RMRCE) [NIAID U54 AI065357]
There are no effective antivirals currently available for the treatment of flavivirus infection in humans. As such, the identification and characterization of novel drug target sites are critical to developing new classes of antiviral drugs. The flavivirus NS5 N-terminal capping enzyme (CE) is vital for the formation of the viral RNA cap structure, which directs viral polyprotein translation and stabilizes the 5' end of the viral genome. The structure of the flavivirus CE has been solved, and a detailed understanding of the CE-guanosine triphosphate (GTP) and CE-RNA cap interactions is available. Because of the essential nature of the interaction for viral replication, disrupting CE-GTP binding is an attractive approach for drug development. The authors have previously developed a robust assay for monitoring CE-GTP binding in real time. They adapted this assay for high-throughput screening and performed a pilot screen of 46 323 commercially available compounds. A number of small-molecule inhibitors capable of displacing a fluorescently labeled GTP in vitro were identified, and a second functional assay was developed to identify false positives. The results presented indicate that the flavivirus CE cap-binding site is a valuable new target site for antiviral drug discovery and should be further exploited for broad-spectrum anti-flaviviral drug development. (Journal of Biomolecular Screening 2011;16:852-861)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据